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Abstract
Background: Cervicogenic headache (CEH) is a unilateral headache localised in the neck or
occipital region, projecting to the frontal and temporal regions. Since the pathogenesis of this
syndrome appears to have an anatomical basis in the cervical region, several surgical procedures
aimed at reducing the nociceptive input on the cervical level, have been tested. We developed a
sequence of various cervical radiofrequency neurotomies (facet joint denervations eventually
followed by upper dorsal root ganglion neurotomies) that proved successful in a prospective pilot
trial with 15 CEH patients. To further evaluate this sequential treatment program we conducted a
randomised controlled trial
Methods: 30 patients with cervicogenic headache according to the Sjaastad diagnostic criteria,
were randomised. 15 patients received a sequence of radiofrequency treatments (cervical facet
joint denervation, followed by cervical dorsal root ganglion lesions when necessary), and the other
15 patients underwent local injections with steroid and anaesthetic at the greater occipital nerve,
followed by transcutaneous electrical nerve stimulation (TENS) when necessary. Visual analogue
scores for pain, global perceived effects scores, quality of life scores were assessed at 8, 16, 24 and
48 weeks. Patients also kept a headache diary.
Results: There were no statistically significant differences between the two treatment groups at
any time point in the trial.
Conclusion: We did not find evidence that radiofrequency treatment of cervical facet joints and
upper dorsal root ganglions is a better treatment than the infiltration of the greater occipital nerve,
followed by TENS for patients fulfilling the clinical criteria of cervicogenic headache.
Background
Cervicogenic headache (CEH) is a unilateral headache
localised in the neck or occipital region, projecting to the
frontal and temporal regions. CEH has been described as
early as 1926 [1]. Sjaastad et al. were the first to give it its
current name [2,3], and these authors formulated diag-
nostic criteria [4-6]. Although CEH as a separate diagnos-
tic entity is still controversial [7], we found that one can
reliably delineate CEH from primary headaches as
migraine and tension-type headache [8]. The prevalence
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of CEH in the general population has been reported to be
0.4 to 2,5 % [6,9,10].
Since the pathogenesis of this syndrome appears to have
an anatomical basis in the cervical region [11,12], several
surgical procedures aimed at reducing the nociceptive
input on the cervical level, have been tested. These include
operative decompression of occipital nerves and cervical
nerve roots [13-15], occipital neurectomy [16,17], cervical
epidural injections [18], cervical manipulations [19-24],
blockades of peripheral nerves with local anaesthetics [25-
28], radiofrequency denervations of the periost of the
occipital bone [29], botulinum toxin injections [30], and
complementary therapies [31]. In a recent review of all
treatments for CEH, Martelletti and van Suijlekom [32]
concluded that consensus on a standard treatment for
CEH does not exist, because of the great variability in
patient selection and clinical effects. Since radiofrequency
cervical facet joint denervations as an isolated treatment
for CEH are often ineffective, we developed a sequence of
various cervical radiofrequency neurotomies (facet joint
denervation followed by dorsal root ganglion neuroto-
mies) that proved successful in a pilot trial with 15
patients [33]. To further evaluate this sequential treatment
program we conducted a randomised controlled trial.
Methods
Patient selection
The study was conducted in the departments of Pain Man-
agement and Research Centre and of Neurology of the
University Hospital of Maastricht, The Netherlands. The
University Hospital Maastricht Institutional Review Board
(Research Ethics Committee) approved the study. All
patients gave a written informed consent before entering
the trial. The study group was recruited from patients with
cervicogenic headache (CEH) according to the diagnostic
criteria of Sjaastad [4]. We discussed the trial design exten-
sively with colleagues of the department of Neurology,
Trondheim University Hospital, Norway, and decided
that the other following inclusion criteria had to be ful-
filled: (1) age between 20 and 65 years; chronic cervico-
genic headache[4] of more than 2 years' duration; (2) an
initial visual analogue scale (VAS) score of more than 50
mm during a pain period; (3) a significant pain during at
least two days per week. Excluded from the study were
patients who had had previous surgical procedures of the
cervical spine; who had coagulation disturbances; who
were pregnant; who had multilevel severe degenerative
changes at their cervical X-ray; who were diagnosed with
post-whiplash syndrome. Patients matching the criteria
for CEH were randomised into two groups: Group I was
the RF-lesion group and Group II was the local injection
group.
Methods in Group I
Patients allocated in Group I first (step 1) had an RF-lesion
of the zygoapophyseal joints at the levels C3–C6 at the
affected side [33]. If -after 8 weeks- the facet denervation
did not relieve the headache sufficiently (see below), the
next step (step 2) was taken: diagnostic cervical segmental
nerve blocks at the levels that were most likely to conduct
an excess of afferent stimuli, were performed [34]. These
levels were identified on physical examination, revealing
tenderness at certain areas which are specific for a segmen-
tal level. At least two adjacent levels were tested at weekly
intervals. When there was a reduction of at least 50 % of
the VAS, an RF lesion adjacent to the relevant dorsal root
ganglion (DRG) was performed [33,34]When there was
no positive diagnostic block or when -after the RF lesion
of the DRG and 8 weeks following the first step- there was
no sufficient relief of the headache (see below), step 3 was
undertaken: Transcutaneous Electrical Nerve Stimulation
(TENS).
Technique of radiofrequency percutaneous facet denervation
The postero-lateral approach was chosen to perform an
RF-lesion of the medial branches of the posterior primary
rami of the facet joints C3–C4, C4–C5 and C5–C6. With the
patient supine on the operating table, a C-arm image
intensifier was positioned in a moderately oblique (+/- 30
%) position, until the projection of the pedicles were seen
a little anterior to 50 % of the vertebral body. In the fron-
tal plane, a small angle of the C-arm with the transversal
plane was obtained to give a clear visibility of the interver-
tebral discs and the neuro-foramina. In this projection,
the medial branch runs over the base of the superior artic-
ular process that is clearly visible. Entry points were
marked on the skin, posterior and caudal to the target
points as seen on the monitor after disinfection of the
skin. A 22 SWG SMK C5 (Radionics, Inc., Burlington, MA)
cannula with a 4-mm active tip was introduced at each
entry point. First the needles were inserted at a maximal
depth of 2 cm in a horizontal plane so that the needle
points were in line with their target points. Subsequently,
each needle was carefully advanced anteriorly and crani-
ally until bone contact was made with the facetal column
at the target point. The position of the needle points was
than checked in the antero-posterior plane: the needle tips
were supposed to project adjacent to the concavity of the
articular pillars of the cervical spine at the corresponding
levels. When an optimal anatomical position of the nee-
dle was reached, this was confirmed by electrical stimula-
tion. The 50 Hz threshold should elicit a response
(tingling sensation) in the neck at < 0,5 Volt and the 2 Hz
stimulation should confirm no muscle movements in the
ipsilateral shoulder and/or arm. Subsequently, 1 ml of
local anaesthetic solution (Lidocaine 2%) was given at
each level and a 60-sec 67°C lesion was made.BMC Anesthesiology 2006, 6:1 http://www.biomedcentral.com/1471-2253/6/1
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Technique of diagnostic block and radiofrequency lesioning of the 
cervical segmental nerves
The patient was lying supine and the C-arm was posi-
tioned obliquely until the contralateral pedicles were pro-
jecting posterior to the anterior line of the vertebral
bodies. In the frontal plane the C-arm was adjusted until
the intervertebral discs were clearly visible. The target
point was posteriorly in the neuroforamen between the
caudal and the middle third part. The entry points were
marked on the skin and were the same as the entry points.
One ml of local anaesthetics (Lidocaine 2%) was injected
in the skin at each entry point and then an RCN-needle
(Radionics. Burlington, MA) was introduced in a tunnel
vision technique. Every step was checked in the lateral
position where the needle tip was supposed to project 1 to
2 mm laterally to the lateral border of the facet column.
After confirming the needle position close to the segmen-
tal nerve with water soluble contrast dye (Iohexol), 0.5 ml
of local anaesthetics (Lidocaine 2%) was injected. After
one or several positive diagnostic blocks, RF lesioning of
the DRG of the involved cervical segmental nerves was
performed. The technique was similar to the technique of
the diagnostic blocks as described above. The differences
were: another needle was used (a 22 SWG SMK C5 can-
nula with a 4-mm active tip, Radionics), the needle tip
was advanced until it was projecting in the middle of the
facet column (to reach the dorsal root ganglion of the seg-
mental nerve) and before the RF lesioning, the 50 Hz and
2 Hz thresholds were looked for. The 50 Hz threshold
should be between > 0, 4 and < 0,65 Volt. The 2 Hz thresh-
old should not occur below a voltage of 1,5 times the 50
Hz threshold. If this was confirmed, 1 ml of Lidocaine 2%
was injected and a RF-lesion was made.
Methods in Group II
The first step in Group II was injection with local anaes-
thetics of the major occipital nerve on the affected side. If
this therapy didn't relieve the headache sufficiently after 8
weeks, the treatment was repeated in step 2. If there was
still no sufficient pain relief after 16 weeks, step 3 was
undertaken: TENS-therapy.
Technique of blocking the greater occipital nerve (GON)
The needle was placed 2 cm. lateral and 2 cm. inferior to
the external occipital protuberance [35]. The needle was
first forwarded onto the periosteum of the occipital bone
and was then withdrawn approximately 0,5 cm. before
injection of local anaesthetic solution. After negative aspi-
ration, 2 ml. of Bupivacaine 0,5 % was injected.
Evaluation
An investigator blinded to the subjects' condition evalu-
ated the patients. This investigator (IEL) did not take part
in the actual treatment process and was thus not aware of
the treatment that the patient had received. Patients were
aware of this and were asked not to mention their received
therapy. As we did not check the blinding efficacy, we can-
not rule out that some unblinding of the investigator actu-
ally took place. We were under the impression that IEL
remained blinded for treatment allocation throughout the
trial. Rating of pain was evaluated by averaging three daily
measurements of the VAS (Visual Analogue Score), rang-
ing from 0 to 100 mm, during one week. We obtained
these ratings from the diary that the patients kept trouh-
gout the trial. This mean VAS of one week was used in the
evaluation of the effect of the treatment (VAS difference
between the different weeks of the treatment). Global per-
ceived effect (GPE) was scored by the patient on a 7-point
scale (ranging from much worse: -3, to 0: no change, to
total pain relief: +3). A sufficient relief of the pain indi-
cated a mean VAS reduction of minimal 20 mm and/or a
good result on the 7-point scale (i.e. complete relief: +3 or
much better: +2). The number of headache days, the med-
icine use and the headache intensity during a week were
also recorded. Follow-up was done by an independent
neurologist (WW) who performed a physical/neurologi-
cal examination at every step of the study. The patient was
also asked to fill in questionnaires: the RAND-36 [36,37],
the MPI-DLV (Multidimensional Pain Inventory in the
Dutch Language) [38,39] and the Dutch version of the
SCL-90 [40,41]. The patients were assessed 4 weeks before
treatment and 8 weeks after treatment. Treatment was
scored as a success, if there was a reduction of the mean
VAS of at least 2 points and/or a global perceived effect of
+2 or +3. Further assessment was conducted at 4, 6, 8, 10
and 12 months after treatment. If failure occurred, the
study provided a "next step" treatment after 2, 4 and 6
months after the initial treatment to avoid the unethical
situation of not treating a patient with pain.
Statistical analysis
The primary endpoint was the percentage of success at 8
weeks (T1). To compare the success rates between the
lesion and the local injection groups, the Chi-square and
if appropriate the Fisher exact tests were performed. P val-
ues = 0.05 were considered statistically significant. Sec-
ondary, the differences between the lesion and the local
injection groups in VAS scores, percentage VAS improv-
ing, mean days of headache, headache intensity and qual-
ity of life domain scores at 8, 16, 24 and 48 weeks were
compared, using a Student's t test.
Results
Demographic and clinical characteristics
From September 1997 until June 2002, 112 consecutive
patients with headache were screened of whom 65 had
Cervicogenic Headache (CEH), according to the criteria
[42]. 35 patients did not enter the study for the following
reasons: 26 did not fulfil the selection criteria and 9BMC Anesthesiology 2006, 6:1 http://www.biomedcentral.com/1471-2253/6/1
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refused to participate in the study. Thirty patients entered
the study and were randomised.
The patient baseline characteristics and psychometric
properties of the Radiofrequency group (Group I) and of
the Local injection group (Group II) are shown in Table 1.
There were no significant group differences in these varia-
bles. The "mean VAS a week" was the mean VAS of the last
7 days (measured three times a day) before entering the
trial. The "days headache a week", the "medicine use a
week" and the "headache intensity a week" were the aver-
ages over the last 4 weeks before entering the trial. The
Rand-36 represents the patients' health concerning the
Physical and Social Function (PF and SF), the Role Physi-
cal and Role Emotional Limitations (RP and RE), the
Mental Health (MH), the Vitality (VI), the Bodily Pain
(BP) and the General Health (GH). These variables were
not significantly different between both groups.
randomisation and follow-up of the study (Figure 1) (Table 
2)
Eight weeks (T1) after the initial treatment, the patient
received a follow-up treatment when the global perceived
effect was 0 or less than zero (no effect:0, little worse:-1,
worse: -2 or much worse:-3). The VAS success wasn't a cru-
cial parameter in making the decision to continue the next
radiofrequency treatment (Group I) or to repeat the local
injection of the greater occipital nerve (Group II).
Group I
There was 1 patient (number 13) in group I who dropped
out of the study on T1 because he refused further partici-
pation in the study, despite of the fact that the GPE was -
2 and thus a follow-up treatment was suggested. In the
evaluation of the effect at the primary endpoint, he was
categorized as a negative responder (see negative VAS
and/or GPE of -2 on T1). There were 4 patients (patient
Table 1: Patient baseline characteristics and psychometric properties
RF (Group I) Control (Group II)
Number of patients (n) 15 15
Mean age (SD) [min/max] (yr) 47,5 (11,0) [22/62] 49,1 (12,8) [28/64]
Male/female (n) 4/11 4/11
Duration of pain (yr) 9,7 6,6
SCL-90 psychoneurotism (SD) 146,3 (29,8) 135,4 (25,0)
Mean VAS/4 weeks (SD) 68,1 (12,7) 76,5 (16,6)
Days headache/4 weeks (SD) 25,9 (5,0) 19,0 (9,3)
Medicine use/week (SD) 6,7 (5,0) 5,8 (8,3)
Headache intensity/week (SD) 2,1 (0,4) 1,9 (0,4)
Rand-36 (SD):
PF 70,0 (21,4) 57,0 (24,6)
SF 71,7 (18,0) 59,2 (23,4)
RP 31,7 (34,7) 36,7 (35,2)
RE 64,4 (38,8) 66,7 (35,6)
MH 65,3 (16,2) 69,6 (16,8)
VI 53,7 (24,3) 45,3 (15,2)
BP 41,8 (19,4) 38,1 (18,5)
GH 58,7 (21,0) 54,7 (18,5)
MPI (SD):
Pain severity 45,6 (9,6) 36,8 (13,6)
Interference 42,0 (14,1) 44,6 (15,9)
Life control 55,0 (8,4) 58,0 (9,2)
Affective distress 48,0 (9,6) 41,9 (9,8)
Support 52,5 (9,8) 51,8 (8,6)
Punishing responses 48,1 (9,5) 45,5 (7,1)
Solicitous responses 53,3 (10,8) 51,3 (10,4)
Distracting responses 50,4 (13,2) 46,5 (9,4)
Household chores 48,4 (9,9) 48,5 (11,1)
Outdoor work 53,5 (9,4) 56,5 (15,9)
Social activities 54,4 (12,0) 52,7 (12,0)
General activity 52,8 (12,0) 53,9 (12,0)BMC Anesthesiology 2006, 6:1 http://www.biomedcentral.com/1471-2253/6/1
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numbers 8, 14, 20 and 23) who did not receive a follow-
up treatment because of a positive GPE (+2) on T1. Two
of them (patient number 14 and 23) continued to have a
positive GPE (+2) after 16 weeks (T2). There were another
3 patients (patient numbers 2, 5 and 19) in the RF group
who did not want a follow-up treatment after 8 weeks (on
T1). Patient number 2 did not want a follow-up treatment
in spite of a negative global perceived effect (GPE = 0) and
a negative VAS-success on T1. The patient only filled in the
pain diary which revealed a positive VAS-success after 16
weeks (T2) without any follow-up treatment. The global
perceived effect was missing. He was categorized as a pos-
itive responder in the evaluation of the primary endpoint.
Patient number 5 and patient number 19 dropped out of
the study after 8 weeks because they were disappointed
with the treatment. They both had a negative global per-
ceived effect (-1 for patient 5 and -2 for patient 19) despite
of the fact that both their VAS successes were positive. In
the evaluation they were accepted to be positive respond-
ers (since they had a positive VAS on T1). There were 7
patients (patient numbers 4, 9, 11, 22, 25, 27 and 30)
who received at least two diagnostic segmental blocks of
cervical nerves (C2, C3 and seldom others). Of them, 4
patients (patient numbers 9, 22, 25 and 30) were not
Flowchart of the study Figure 1
Flowchart of the study.BMC Anesthesiology 2006, 6:1 http://www.biomedcentral.com/1471-2253/6/1
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Table 2: Randomisation and follow-up of the study patients
T0 Step I T1 (= 8 weeks) Step II T2 (= 16 weeks) Step III
Patient number Randomization GPE VAS success Follow-up treatment GPE VAS success TENS
1 GON 0 _ GON -1 _ Yes, -
2 PFD C3–C6 0 _ Patient does not want follow-up 
treatment
Missing + No
3 GON +2 _ No 0, again GON _ No
4 PFD C3–C6 +1 + Prog C2, prog C3
Policy: RF C2
Missing + No
5 PFD C3–C6 -1 + Patient does not want follow-up 
treatment
OS OS OS
6 GON -1 + GON 1 + No
7 GON 0 + Heart catheterization, no follow-up 
treatment
2_ N o
8 PFD C3–C6 +2 _ No 1 + No
9 PFD C3–C6 0 _ Progn. C2, C3, C5: all no effect 0 + Yes, -
10 GON +1 + GON 2 _ Yes, +
11 PFD C3–C6 +1 + Prog C2, prog C3
Policy: RF C2
1+ Y e s ,  +
12 GON +2 + No 2 + No
13 PFD C3–C6 -2 _ Yes, but patient had no time to come 
anymore
OS OS OS
14 PFD C3–C6 +2 _ No 2 Missing No
15 GON +3 Missing No 2 _ No
16 GON +1 + GON 0 + Yes, +
17 GON -2 _ GON 1 Missing Yes, +
18 GON 0 + PFD C3-C6 0 + Yes, -
19 PFD C3–C6 -2 + OS, not very content with the 
treatment
OS OS OS
20 PFD C3–C6 +2 + No -2 _ Yes, +
21 GON +2 + No 2 + No
22 PFD C3–C6 0 + Progn. C2, progn. C3: all no effect 1 + Yes, -
23 PFD C3–C6 +2 + No 2 + No
24 GON +1 + GON 0 _ Yes, OS
25 PFD C3–C6 0 + Progn. C2, C3, C4: all no effect 0 + Yes, -
26 GON OS Missing OS OS Missing OS
27 PFD C3–C6 0 + Progn. C2, C3.
Policy: RF C3
+1 + Yes, -
28 GON +1 _ GON -2 _ Yes, +
29 GON -2 _ OS, does not want any treatment OS OS OS
30 PFD C3–C6 0 + Progn. C2, C3: all no effect -2 _ Yes, +
GON = Greater Occipital Nerve
PFD = Percutaneous Facet Denervation
GPE = Global Perceived Effect (-3 = much worse, -2 = worse, -1 = little worse, 0 = no effect, +1 = improved, +2 = much improved, +3 = no 
complaints anymore)
VAS = Visual Analogue Score (+ = success, - = no success)
OS = Off Study
TENS = Transcutaneous Electrical Nerve Stimulation (+ = success, - = no success)
treated with a radiofrequency lesion of a cervical segmen-
tal nerve because of negative diagnostic blocks. Patient
number 4 was treated with an RF of the DRG of C2 and
patient numbers 11 and 27 were treated with RF of the
DRG of C3 because of positive diagnostic blocks. None of
them reported a positive GPE after 16 weeks (T2), but they
all reported a positive VAS success. In the evaluation of the
effect at the primary endpoint (T1), patient number 9 was
classified as non-successful (GPE of 0 and negative VAS
success on T1) and patients numbers 22, 25 and 30 were
called to be successful (they all reported a positive VAS
success on T1).
Group II
In the local injection group (Group II) there was one
patient (patient number 26) who did not show up on T1
and on later evaluations. He dropped out because he
started oral analgesics that reduced his pain significantly.
He was categorized as "off study" (OS). Furthermore there
were 7 patients (patient numbers 3, 7, 12, 15, 18, 21 andBMC Anesthesiology 2006, 6:1 http://www.biomedcentral.com/1471-2253/6/1
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29) in this group that did not receive a second local injec-
tion of the greater occipital nerve on T1. Four of them
(patient numbers 3, 12, 15 and 21) had a GPE of +2 or +3
and therefore a follow-up treatment was not given in the
study protocol. Of the other 4 patients, one patient
(number 3) asked for a second local injection treatment
16 weeks after the initial treatment (on T2) because his
global perceived effect was decreased from +2 (on T1) to
0. In the evaluation of the effect on the primary endpoint,
he was considered a treatment success The other three
patients (patient numbers 12, 15 and 21) who did not
receive a second local injection of the greater occipital
nerve, because they all had a positive GPE (+2) on T1,
reported a long-lasting positive effect (GPE +2 after 16
weeks (T2)). Of the other 3 patients (patient numbers 7,
18 and 29) that did not receive a second local injection of
the greater occipital nerve, despite of the fact that they
reported a negative GPE (0 or -2), one patient (patient
number 7) underwent a heart catheterization because of
occlusive coronary vascular disease. Nevertheless, he con-
tinued to fill in the pain diary and the question lists and
was thus included in the final evaluation of the technique
and he was categorized as a positive responder (VAS suc-
cess + on T1  and GPE = +2 on T2). Another patient
(patient number 29) didn't want a follow-up invasive
treatment anymore despite of the negative GPE (-2) and
the negative VAS success after 8 weeks (T1). He dropped
out because he was not very content with the first treat-
ment. In the final evaluation of the technique, he was cat-
egorized as negative responder (since he had a negative
Table 4: Number of patients with a positive GPE and/or a successful VAS at different times in the study (T1, T2 and T6).
T1 (= 8 weeks) T2 (= 16 weeks) T6 (= 1 year)
Group I Group II Total Group I Group II Total Group I Group II Total
n with success 
(%)
12 (80%) 10 (66,7%) 22 (73,3%) 10 (66,7%) 8 (53,3%) 18 (60%) 8 (53,3%) 7 (46,7%) 15 (50%)
n no success (%) 3 (20%) 4 (26,7%) 7 (23,3%) 2 (13,3%) 5 (33,3%) 7 (23,3%) 2 (13,3%) 3 (20%) 5 (16,7%)
n no data (%) 1 (6,7%) 1 (3,3%) 3 (20%) 2 (13,3%) 5 (16,7%) 5 (33,3%) 5 (33,3%) 10 (33,3%)
Group I = Radiofrequency treatment group
Group II = Local injection group
Table 3: VAS, quantity of days of headache and intensity of headache at different timesin the study (T1, T2, T3 and T6) compared with 
T0
RF (Group I) Mean (SD) Control (Group II) Mean (SD) p 95% CI
VAS difference
T1-T0 30,5 (17,3) 32,4 (24,7) 0,81 -14,4 to 18,3
T2-T0 29,9 (13,8) 21,0 (35,5) 0,41 -31,2 to 13,5
T3-T0 28,9 (20,3) 24,6 (35,0) 0,69 -26,6 to 17,9
T6-T0 30,2 (12,4) 26,8 (37,7) 0,75 -25,8 to 19,1
Headache difference
T0 T1 4,2 (5,1) 5,5 (8,7) 0,62 -4,3 to 7,1
T0 T2 4,1 (4,1) 3,9 (6,3) 0,94 -4,5 to 4,2
T0 T3 7,5 (7,1) 4,5 (6,1) 0,27 -8,3 to 2,4
T0 T6 5,6 (5,7) 6,8 (7,7) 0,65 -4,2 to 6,7
Intensity difference
T0 T1 1,5 (4,0) - 0,5 (8,7) 0,43 -3,1 to 7,1
T0 T2 2,3 (4,2) -1,0 (9,6) 0,23 -2,2 to 8,9
T0 T3 3,1 (4,5) - 0,6 (9,2) 0,18 -1,8 to 9,2
T0 T6 3,7 (8,7) - 0,4 (9,4) 0,24 -2,9 to 10,9
Percentage VAS improving
T1 43,9 (22,0) 42,4 (28,6) 0,87 -21,2 to 18,1
T2 45,4 (23,9) 24,1 (50,1) 0,17 -52,0 to 9,5
T3 41,7 (28,5) 28,0 (49,4) 0,38 -45,0 to 17,6
T6 44,4 (16,8) 30,7 (49,9) 0,34 -43,5 to 16,1
VAS difference = mean difference of VAS on T1, T2, T3 and T6 compared with T0 in mm mean VAS is the mean VAS of one week (three times a 
day) before T1, T2, T3 or T3
Headache difference = mean days of headache 4 weeks before T1, T2, T3 and T6 compared with mean days of headache before T0
Intensity difference of headache = mean days of heavy pain intensity 4 weeks before T1, T2, T3 and T6 compared with heavy pain intensity before 
T0.
Percentage VAS improving = mean VAS improved on T1, T2, T3 and T6 compared with T0 in %.BMC Anesthesiology 2006, 6:1 http://www.biomedcentral.com/1471-2253/6/1
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VAS success and a GPE of -2 on T1). Patient number 18
did not believe in the local injection technique despite of
the positive VAS success on T1 and demanded a percuta-
neous facet denervation of the C3 to C6 facet joints on T1.
This patient was included in the evaluation of the local
injection group (Group II) after 8 weeks, but was excluded
in the further evaluations of the local injection technique
because of his cross-over to the RF treatment. Seven
patients of the local injection group (patient number 1, 6,
10, 16, 17, 24 and 28) received a second local injection of
the greater occipital nerve on T1 because of a "negative"
GPE (i.e. +1, 0, -1 or -2). Patient number 1, 17, 24 and 28
reported a negative outcome on T2 after the repeated local
injection. They were assessed to try out TENS. The other 3
patients (patient number 6, 10 and 16) reported or a pos-
itive GPE (patient number 10) or a positive VAS-success
(patient number 6 and 16) on T2. Patient number 6 did
not try out TENS, patient numbers 10 and 16 tried out the
TENS although they reported a positive GPE (+2 for
patient number 10) or a positive VAS success (patient
number 16).
Difference in VAS, days of headache and intensity of 
headache of both groups compared to the initial values 
(Table 3)
The VAS difference between the different moments (T1,
T2, T3 and T6) compared to the initial VAS (T0) showed
an improvement at every moment in the study in each
group. Between both groups there was no significant dif-
ference in improvement.
The amount of headache days on the different moments
(T1, T2, T3 and T6) compared to T0 decreased during the
study and this was not significantly different in Group I
compared to Group II.
The difference in headache intensity in which the inten-
sity of the headaches on the different moments (T1, T2, T3
Comparison of mean health domains at different follow-up measurements for both groups (I = Radiofrequency Group and II =  Local injection group) Figure 2
Comparison of mean health domains at different follow-up measurements for both groups (I = Radiofrequency Group and II = 
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and T6) where compared to the headache intensity before
T0, seemed to be better at each moment in Group II com-
pared to Group I, although these differences where not
significant!
In the RF-group the percentage of improved VAS com-
pared to T0 was not significantly different between the dif-
ferent moments, namely between 41,7 and 45,4%. In
Group II, the percentage of the improved VAS was the
highest on T0/T1 (42,4 %) compared to the lowest per-
centage of improvement on T0/T2 (28,0 %). These out-
comes where not significant different. Furthermore, there
was no significant difference in VAS improvement
between both groups.
Positive global perceived effects (GPE of +2 or +3) and/or 
a successful VAS-difference (Table 4)
Eight weeks after the initial treatment (T1), 80% of the
patients in the RF-group (Group I) and 66,7% of the
patients in the local injection group (Group II) reported a
successful treatment in terms of a positive global per-
ceived effect and/or an VAS reduction of at least 50% com-
pared to the initial VAS. This meant no statistically
significant difference in success rate between both groups.
Sixteen weeks after the initial treatment (T2), the success
rate in Group I was 66,7% compared to 55,3% in Group
II. Again, this difference is not statistically significant.
After one year (T6), there was no difference of the success
rate in Group I (53,3%) compared to Group II (50%). A
relatively high percentage of patients (33,3%) in both
groups were not followed anymore because of several rea-
sons. The most important reason was the disappointment
in the treatment.
Mean health scores in the RF-group (Group I) and the 
GON-group (Group II) at different times (T0, T1, T2 and 
T6) (Figure 2)
This figure shows no significantly difference between the
mean health scores of both groups at different moments.
Discussion
The primary goal of this study was to compare the efficacy
of a radiofrequency treatment with a treatment by local
injection of the greater occipital nerve in patients with cer-
vicogenic headache (CEH). Although CEH is a controver-
sial diagnosis[7], it is a widely used diagnosis for which
radiofrequency treatment is given in routine clinical care.
As the scientific basis for this therapy is also controversial,
we sought to restrict ourselves to a clearly defined head-
ache syndrome. We demonstrated earlier that CEH can be
relatively reliably delineated from the other primary head-
aches[8]. We feel that the rigorous selection of patients
such as we did for this trial (see below) led to a rather
homogenous group of CEH patients. These patients, with
a strictly unilateral headache without side-shift and pain
originating in the neck, were shown by Antonaci et
al[43]to be most reliably diagnosable as CEH. Most of
these would proably also fulfill the International Head-
ache Classification criteria for CEH[44]. Much effort was
spent to select patients with CEH according to recent cri-
teria[42]; we screened 112 patients, of which only 30
entered our study.
We thus randomised 30 patients with cervicogenic head-
ache into two groups receiving either treatment. In the dif-
ferent steps of the study, the patients could get a follow-up
treatment if the first treatment was not successful or only
had a short period of success. We undertook this study,
encouraged by the success of our earlier open trial with
good results after long-term follow-up [33] Because of the
setup of the trial (we compared two possible sequences of
treatments, rather than two isolated ones), conclusions on
isolated treatment effects cannot be made. But we may
conclude that a sequence of possible radiofrequency treat-
ments (beginning with a cervical facet joint denervation)
is not better than a more conservative sequence of thera-
pies including local injections and TENS. This is reflected
in the primary outcome measure (pain and global per-
ceived effect at 8 weeks) and also in the secondary out-
come parameters, at any given time point in the study. The
positive effects we observed in our earlier open study [33],
probably reflects the less rigorous methodology of that
trial. In fact we have observed a similar phenomenon (less
clinical effect with better trial methodology) when we
studied the effects of intradiscal radiofrequency therapy
for low back pain [45,46]. Because of the lack of difference
between the two treatment groups, we feel that the blind-
ing of the evaluating investigator in the present study was
relatively good, as one would expect a possible bias to
emerge preferably in the more invasively treated group.
To this date only one other randomised controlled trial
was undertaken to study the efficacy of a radiofrequency
denervation of cervical facet joints in patients with cervi-
cogenic headache [47]. They randomised patients in two
groups of each 6 patients to receive an RF neurotomy of
facet joints C2 C6 ipsilateral to the pain, or a sham treat-
ment. They found a minor improvement in patients
treated with an RF denervation at 3 months, but later on
there were no marked differences between groups.
Conclusion
We did not find evidence that RF treatment of cervical
facet joints and dorsal root ganglion is an effective treat-
ment for patients fulfilling the clinical criteria of cervico-
genic headache. We do share the concern of Stovner et al
that many such patients are treated with these neuroto-
mies despite lack of robust evidence for positive effects
[47].BMC Anesthesiology 2006, 6:1 http://www.biomedcentral.com/1471-2253/6/1
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